{"entity":{"id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of Adebrelimab and SHR-1501 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors is a phase 1/2 interventional study registered as NCT07073534 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 203 participants planned, started 2025-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-1501, Adebrelimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07073534","url":"https://clinicaltrials.gov/study/NCT07073534"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["adebrelimab","shr-1501"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07073534","phase":"1/2","setting":"Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":203,"outcomes":[]},"route":"/trials/nct07073534/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}